Corporate Profile

Aileron Therapeutics is a clinical stage company discovering and developing novel medicines for the treatment of cancer and cancer-supportive care by targeting high-value and historically undruggable intracellular targets using a proprietary platform of stabilized cell-permeating peptides. Our lead product candidate, ALRN-6924, is a first-in-class dual MDM2/MDMX inhibitor that has been tested in hematologic cancer and is currently being evaluated in a Phase 2 clinical trial in combination with Pfizer’s palbociclib (Ibrance®) for the treatment of MDM2-amplified advanced solid tumors, and in a Phase 1b/2 clinical trial to evaluate ALRN-6924 as a myelopreservative agent to protect against chemotherapy-induced toxicities. Emerging ALRN-6924 clinical results and substantial preclinical data  support its use across multiple cancer types as a monotherapy or as a combination therapy with targeted agents, chemotherapies, and immuno-oncology drugs. Aileron is exploring collaboration opportunities regarding ALRN-6924  and in other areas where Aileron’s proprietary platform of stabilized cell-permeating peptides can be applied such as targeted protein degradation and the Bcl-2 family of cancer targets.